亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial

医学 安慰剂 冲程(发动机) 阿司匹林 人口 氯吡格雷 临床终点 风险因素 内科学 随机对照试验 麻醉 病理 机械工程 环境卫生 工程类 替代医学
作者
Mukul Sharma,Carlos A. Molina,Ḱazunori Toyoda,Dániel Bereczki,Shrikant I. Bangdiwala,Scott E. Kasner,Helmi L. Lutsep,Georgios Tsivgoulis,George Ntaios,Anna Członkowska,Ashfaq Shuaib,Pierre Amarenco,Matthias Endres,Byung‐Woo Yoon,David Tanné,Danilo Toni,Laetitia Yperzeele,Paul von Weitzel-Mudersbach,Gisele Sampaio Silva,Álvaro Avezum,Jesse Dawson,Daniel Strbian,Turgut Tatlisumak,Jens Eckstein,Sebastián F. Ameriso,Joerg R. Weber,Else Charlotte Sandset,Nana Goar Pogosova,Pablo M Lavados,Antonio Araúz,David Gailani,Hans‐Christoph Diener,Richard A. Bernstein,Charlotte Cordonnier,Anja Kahl,Grigor Abelian,Mark Donovan,Chahin Pachaï,Danshi Li,Graeme J. Hankey
出处
期刊:Lancet Neurology [Elsevier]
卷期号:23 (1): 46-59 被引量:32
标识
DOI:10.1016/s1474-4422(23)00403-9
摘要

Background People with factor XI deficiency have lower rates of ischaemic stroke than the general population and infrequent spontaneous bleeding, suggesting that factor XI has a more important role in thrombosis than in haemostasis. Milvexian, an oral small-molecule inhibitor of activated factor XI, added to standard antiplatelet therapy, might reduce the risk of non-cardioembolic ischaemic stroke without increasing the risk of bleeding. We aimed to estimate the dose–response of milvexian for recurrent ischaemic cerebral events and major bleeding in patients with recent ischaemic stroke or transient ischaemic attack (TIA). Methods AXIOMATIC-SSP was a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial done at 367 hospitals in 27 countries. Eligible participants aged 40 years or older, with acute (<48 h) ischaemic stroke or high-risk TIA, were randomly assigned by a web-based interactive response system in a 1:1:1:1:1:2 ratio to receive one of five doses of milvexian (25 mg once daily, 25 mg twice daily, 50 mg twice daily, 100 mg twice daily, or 200 mg twice daily) or matching placebo twice daily for 90 days. All participants received clopidogrel 75 mg daily for the first 21 days and aspirin 100 mg daily for the first 90 days. Investigators, site staff, and participants were masked to treatment assignment. The primary efficacy endpoint was the composite of ischaemic stroke or incident covert brain infarct on MRI at 90 days, assessed in all participants allocated to treatment who completed a follow-up MRI brain scan, and the primary analysis assessed the dose–response relationship with Multiple Comparison Procedure–Modelling (MCP-MOD). The main safety outcome was major bleeding at 90 days, assessed in all participants who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov (NCT03766581) and the EU Clinical Trials Register (2017-005029-19). Findings Between Jan 27, 2019, and Dec 24, 2021, 2366 participants were randomly allocated to placebo (n=691); milvexian 25 mg once daily (n=328); or twice-daily doses of milvexian 25 mg (n=318), 50 mg (n=328), 100 mg (n=310), or 200 mg (n=351). The median age of participants was 71 (IQR 62–77) years and 859 (36%) were female. At 90 days, the estimates of the percentage of participants with either symptomatic ischaemic stroke or covert brain infarcts were 16·8 (90·2% CI 14·5–19·1) for placebo, 16·7 (14·8–18·6) for 25 mg milvexian once daily, 16·6 (14·8–18·3) for 25 mg twice daily, 15·6 (13·9–17·5) for 50 mg twice daily, 15·4 (13·4–17·6) for 100 mg twice daily, and 15·3 (12·8–19·7) for 200 mg twice daily. No significant dose–response was observed among the five milvexian doses for the primary composite efficacy outcome. Model-based estimates of the relative risk with milvexian compared with placebo were 0·99 (90·2% CI 0·91–1·05) for 25 mg once daily, 0·99 (0·87–1·11) for 25 mg twice daily, 0·93 (0·78–1·11) for 50 mg twice daily, 0·92 (0·75–1·13) for 100 mg twice daily, and 0·91 (0·72–1·26) for 200 mg twice daily. No apparent dose–response was observed for major bleeding (four [1%] of 682 participants with placebo, two [1%] of 325 with milvexian 25 mg once daily, two [1%] of 313 with 25 mg twice daily, five [2%] of 325 with 50 mg twice daily, five [2%] of 306 with 100 mg twice daily, and five [1%] of 344 with 200 mg twice daily). Five treatment-emergent deaths occurred, four of which were considered unrelated to the study drug by the investigator. Interpretation Factor XIa inhibition with milvexian, added to dual antiplatelet therapy, did not substantially reduce the composite outcome of symptomatic ischaemic stroke or covert brain infarction and did not meaningfully increase the risk of major bleeding. Findings from our study have informed the design of a phase 3 trial of milvexian for the prevention of ischaemic stroke in patients with acute ischaemic stroke or TIA. Funding Bristol Myers Squibb and Janssen Research & Development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汤汤完成签到 ,获得积分10
6秒前
上官若男应助科研通管家采纳,获得10
50秒前
无花果应助科研通管家采纳,获得10
51秒前
疯狂喵完成签到 ,获得积分10
1分钟前
谢小盟完成签到 ,获得积分10
1分钟前
1分钟前
seren_liu发布了新的文献求助10
1分钟前
张张完成签到 ,获得积分10
2分钟前
ldysaber完成签到,获得积分10
2分钟前
ma完成签到 ,获得积分10
2分钟前
xiangwang完成签到 ,获得积分10
2分钟前
想不出来完成签到 ,获得积分10
2分钟前
2分钟前
3分钟前
小凯完成签到 ,获得积分10
3分钟前
3分钟前
chxxxxx发布了新的文献求助30
3分钟前
franklin发布了新的文献求助10
3分钟前
万能图书馆应助chxxxxx采纳,获得10
3分钟前
微笑语柳完成签到,获得积分10
3分钟前
NexusExplorer应助franklin采纳,获得10
3分钟前
3分钟前
3分钟前
3分钟前
elle发布了新的文献求助10
3分钟前
充电宝应助elle采纳,获得10
3分钟前
elle完成签到,获得积分20
4分钟前
franklin完成签到,获得积分20
4分钟前
YYYY完成签到 ,获得积分10
4分钟前
香蕉觅云应助科研通管家采纳,获得10
4分钟前
4分钟前
小学生的练习簿完成签到,获得积分10
5分钟前
5分钟前
xx发布了新的文献求助10
5分钟前
5分钟前
6分钟前
小马甲应助泡面小猪采纳,获得10
6分钟前
蟹黄小笼包完成签到,获得积分10
6分钟前
6分钟前
LZL完成签到,获得积分10
7分钟前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137011
求助须知:如何正确求助?哪些是违规求助? 2787960
关于积分的说明 7784091
捐赠科研通 2444041
什么是DOI,文献DOI怎么找? 1299627
科研通“疑难数据库(出版商)”最低求助积分说明 625497
版权声明 600989